Topiramate (Epilepsy)

Digestive system anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12871
R48605		 Thomas (Topiramate) (Controls exposed to Lamotrigine, sick), 2021 Gastro-intestinal malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 5.82 [0.11;313.84] C
excluded (control group) 		0/9   0/50 0 9
ref
S12872
R48615		 Thomas (Topiramate) (Controls unexposed, sick), 2021 Gastro-intestinal malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 13.27 [0.50;350.05] C 0/9   1/340 1 9
ref
S6061
R15762		 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 Gastrointestinal tract defects 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 3.34 [0.17;66.32] C 0/28   3/647 3 28
ref
Total 2 studies 6.26 [0.69;56.84] 4 37
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Thomas (Topiramate) (Controls unexposed, sick), 2021Thomas, 2021 1 13.27[0.50; 350.05]1945%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 3.34[0.17; 66.32]32855%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 6.26[0.69; 56.84]4370.950.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Controls unexposed, sick; 2: Topiramate) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 6.26[0.69; 56.84]4370%NAThomas (Topiramate) (Controls unexposed, sick), 2021 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 13.27[0.50; 350.05]19 -NAThomas (Topiramate) (Controls unexposed, sick), 2021 1 exposed to other treatment, sickexposed to other treatment, sick 3.34[0.17; 66.32]328 -NAMorrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 6.26[0.69; 56.84]4370%NAThomas (Topiramate) (Controls unexposed, sick), 2021 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 2 All studiesAll studies 6.26[0.69; 56.84]4370%NAThomas (Topiramate) (Controls unexposed, sick), 2021 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 20.550.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12871

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Out of scale13.27[0.50; 350.05]19 -NAThomas (Topiramate) (Controls unexposed, sick), 2021 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 4.08[0.37; 44.58]3370%NAThomas (Topiramate) (Controls exposed to Lamotrigine, sick), 2021 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0